Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen's H1 Revenues Rise 18 Percent

NEW YORK (GenomeWeb News) – French molecular diagnostics firm IntegraGen today said that revenues during the first half of 2013 increased 18 percent year over year.

The company, which develops MDx tests for autism and cancer, said that during the first six months of the year it posted revenues of €2.7 million ($3.7 million), compared to €$2.3 million a year ago. IntegraGen preannounced preliminary first-half 2013 revenues in July.

The company posted a net loss for H1 2013 of €1.4 million, down from €999,000 a year ago. Operating expenses increased 26 percent to €2.9 million from €2.3 million a year ago, it said.

IntegraGen finished the half-year with €2.9 million in cash.

The firm's flagship product is its Arisk test for identifying the risk of autism in siblings of individuals previously diagnosed with autism spectrum disorder. Today, IntegraGen said that it anticipates launching a second version of the test for children who display signs of developmental delay or who have signs of autism, but who have no family history of autism.

Earlier this month IntegraGen announced the acquisition of rights to a microRNA biomarker for predicting patient outcomes in metastatic colorectal cancer from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique — Hopitaux de Paris.

The company said that its activities "should keep the pace of a double-digit growth in 2013."